Innate Pharma (IPHA) shares rallied 29% on positive phase 2 trial data for monalizumab plus durvalumab in non-small cell lung cancer patients.
Surface Oncology (SURF) shares rose 14% following an uptick in the previous session.
Beigene (BGNE) shares surged 14% after the company received a positive opinion from a key European Medicines Agency committee recommending approval of brukinsa to treat Waldenstrom's macroglobulinemia.
|Goldman Sachs Upgrades GitLab to Buy From Neutral, A...|
|Goldman Sachs Adjusts Price Target on Lowe's to $205...|
|Goldman Sachs Adjusts Ulta Beauty's Price Target to ...|
|--Street Color: May preliminary capital goods shipme...|
|--Street Color: May preliminary capital goods orders...|